VXRT stock forecast
Our latest prediction for Vaxart Inc's stock price was made on the May 22, 2020 when the stock price was at 2.91$.
In the short term (2weeks), VXRT's stock price should outperform the market by 0.87%. During that period the price should oscillate between -12.74% and +17.02%.
In the medium term (3months), VXRT's stock price should underperform the market by -5.16%. During that period the price should oscillate between -39.99% and +37.39%.Get email alerts
Create a solid portfolio with VXRT
About Vaxart Inc
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
At the moment the company generates 7M USD in revenues.
On its last earning announcement, the company reported a loss of -0.70$ per share.
The book value per share is 3.13$
Three months stock forecastMay 22, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|